Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apidra Premeal vs Postmeal in Type 2 Diabetes
NCT00135096Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in weight from baseline to study week 52. Started Aug 2004; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00135096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135096.